Pulse Biosciences Launches Pivotal Study for Atrial Fibrillation Treatment — Pulse Biosciences, Inc.

Event summary

Pulse Biosciences enrolled the first seven patients in its NANOPULSE-AF study, evaluating the nPulse™ Cardiac Catheter System for treating drug-resistant atrial fibrillation.
The study is a prospective, multicenter IDE pivotal clinical investigation planned to enroll approximately 215 participants across up to 30 centers in the U.S. and Europe.
Initial feasibility results showed 96% procedural success at 12 months with no anti-arrhythmic drugs required.
The nPulse™ system integrates with Abbott’s EnSite X 3D electroanatomical mapping system for enhanced visualization and workflow efficiency.

The big picture

Pulse Biosciences' entry into the atrial fibrillation treatment market with its innovative nsPFA technology marks a significant shift in cardiac ablation techniques. The company aims to disrupt a field dominated by thermal-based systems, leveraging non-thermal energy for more precise and efficient procedures. Success in this pivotal study could position Pulse Biosciences as a key player in the growing market for advanced cardiac care solutions.

What we're watching

Clinical Efficacy: Whether the nPulse™ system can sustain its high procedural success rates in a larger, multicenter setting.
Market Differentiation: How Pulse Biosciences' nanosecond pulsed field ablation technology will compete against existing atrial fibrillation treatments.
Regulatory Approval: The pace at which the NANOPULSE-AF study results could lead to regulatory approval and commercialization of the nPulse™ system.